ONKURE THERAPEUTICS INC-A
OKURNASDAQTrading Snapshot
- Day Range
- $4.04 – $4.16
- 52-Week Range
- $1.93 – $5.38
- Volume
- $1.59B
- Avg Volume
- $2.03B
- Shares Outstanding
- 40.5M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $6M
- P/E Ratio
- -1.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.18
- Dividend Yield
- 0.00%
Why Investors Own OKUR
- ✓High-growth profile — revenue up -6.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ONKURE THERAPEUTICS INC-A
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.
CORRECTION: OnKure Therapeutics Q2 EPS $(0.31) Beats $(0.54) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share
OnKure Therapeutics Announces Registration Of Up To $100M At-The-Market Offering Of Class A Common Stock Through Leerink Partners
https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm
HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.